The Commission is now operating in accordance with the Caretaker ConventionsExternal link pending the outcome of the 2025 federal election.
This resource lists the eight quality statements in the clinical care standard that aim to ensure the safe and appropriate use of psychotropic medicines in people with cognitive disability or impairment.
The standard contains eight quality statements that describe the health care you should receive to support the correct use of psychotropic medicines. This fact sheet explains each quality statement and what it means for you.
The Psychotropic Medicines in Cognitive Disability or Impairment Clinical Care Standard contains eight quality statements and seven indicators to ensure the safe and appropriate use of psychotropic medicines in people with cognitive disability or impairment and uphold their rights, dignity, health and quality of life.
The Commission is hosting two upcoming webinars in June/July on implementation of the National Clinical Trials Governance Framework (the Governance Framework).
This issue includes items on implementation, value, COVID-19, and more. Also covered are the latest from BMJ Quality & Safety, Australian Prescriber, Patient Experience Journal (PXJ), Healthcare Policy and Health Expectations along with the latest from the UK’s NIHR and the USA’s AHRQ.
Tell us how we can improve your newsletter experience.